146 related articles for article (PubMed ID: 12716772)
1. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans.
Hossain MA; Reyes GH; Long LA; Mukherjee PK; Ghannoum MA
J Antimicrob Chemother; 2003 Jun; 51(6):1427-9. PubMed ID: 12716772
[TBL] [Abstract][Full Text] [Related]
2. Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model.
Goldblum D; Frueh BE; Sarra GM; Katsoulis K; Zimmerli S
Antimicrob Agents Chemother; 2005 Apr; 49(4):1359-63. PubMed ID: 15793112
[TBL] [Abstract][Full Text] [Related]
3. [Successful treatment with caspofungin of an invasive candidosis resistant to liposomal amphotericin B in a neutropenic patient].
Rome A; André N; Michel A; Coze C; Gentet JC; Bernard JL
Arch Pediatr; 2006 Dec; 13(12):1556-7. PubMed ID: 17049216
[No Abstract] [Full Text] [Related]
4. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
5. Efficacies of caspofungin and a combination of caspofungin and meropenem in the treatment of murine disseminated candidiasis.
Ozcan SK; Budak F; Willke A; Filiz S; Costur P; Dalcik H
APMIS; 2006 Dec; 114(12):829-36. PubMed ID: 17207082
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice.
Maesaki S; Hossain MA; Miyazaki Y; Tomono K; Tashiro T; Kohno S
Antimicrob Agents Chemother; 2000 Jun; 44(6):1728-30. PubMed ID: 10817741
[TBL] [Abstract][Full Text] [Related]
7. Caspofungin in combination with amphotericin B against Candida parapsilosis.
Barchiesi F; Spreghini E; Tomassetti S; Giannini D; Scalise G
Antimicrob Agents Chemother; 2007 Mar; 51(3):941-5. PubMed ID: 17158939
[TBL] [Abstract][Full Text] [Related]
8. Antifungal therapies in murine infections by Candida kefyr.
Sanchis M; Martin-Vicente A; Capilla J; Guarro J
Mycoses; 2016 Apr; 59(4):253-258. PubMed ID: 26857550
[TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to echinocandins in Candida albicans: case report and review.
Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of the combination of caspofungin and terbinafine against Candida albicans, Candida dubliniensis and Candida kefyr.
Gil-Lamaignere C; Müller FM
Int J Antimicrob Agents; 2004 May; 23(5):520-3. PubMed ID: 15120736
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model.
Imai J; Singh G; Fernandez B; Clemons KV; Stevens DA
J Antimicrob Chemother; 2005 Jul; 56(1):166-71. PubMed ID: 15917284
[TBL] [Abstract][Full Text] [Related]
12. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species.
Karlowsky JA; Hoban DJ; Zhanel GG; Goldstein BP
Int J Antimicrob Agents; 2006 Feb; 27(2):174-7. PubMed ID: 16414247
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of cilofungin and amphotericin B on experimental murine candidiasis.
Morrison CJ; Stevens DA
Antimicrob Agents Chemother; 1990 May; 34(5):746-50. PubMed ID: 2193617
[TBL] [Abstract][Full Text] [Related]
14. Antifungal resistance: the clinical front.
Perfect JR
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 13):15-22. PubMed ID: 15682590
[TBL] [Abstract][Full Text] [Related]
15. Caspofungin versus amphotericin B for the treatment of Candidal esophagitis.
Chocarro Martínez A; Gonzalez A; Garcia I
Clin Infect Dis; 2002 Jul; 35(1):107; author reply 107-8. PubMed ID: 12060888
[No Abstract] [Full Text] [Related]
16. In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves.
Li Y; Sun S; Guo Q; Ma L; Shi C; Su L; Li H
J Antimicrob Chemother; 2008 Mar; 61(3):577-85. PubMed ID: 18194958
[TBL] [Abstract][Full Text] [Related]
17. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis.
Sionov E; Mendlovic S; Segal E
J Infect; 2006 Aug; 53(2):131-9. PubMed ID: 16360214
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin therapy of neonates with invasive candidiasis.
Odio CM; Araya R; Pinto LE; Castro CE; Vasquez S; Alfaro B; Sàenz A; Herrera ML; Walsh TJ
Pediatr Infect Dis J; 2004 Dec; 23(12):1093-7. PubMed ID: 15626944
[TBL] [Abstract][Full Text] [Related]
20. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
